Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance

CD38 and B-cell maturation antigens (BCMAs) are prevalently expressed on neoplastic plasma cells in multiple myeloma (MM), making them ideal therapeutic targets. Anti-CD38 monoclonal antibodies, such as approved daratumumab and isatuximab, are currently the milestone in MM treatment because they ind...

Descripción completa

Detalles Bibliográficos
Autores principales: De Novellis, Danilo, Fontana, Raffaele, Giudice, Valentina, Serio, Bianca, Selleri, Carmine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820921/
https://www.ncbi.nlm.nih.gov/pubmed/36614086
http://dx.doi.org/10.3390/ijms24010645

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820921/
https://www.ncbi.nlm.nih.gov/pubmed/36614086
http://dx.doi.org/10.3390/ijms24010645

Ejemplares similares